- Home
- IMNN vs RLMD Comparison
IMNN vs RLMD Comparison
Compare IMNN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- RLMD
- Stock Information
- Founded
- IMNN 1982
- RLMD 2004
- Country
- IMNN United States
- RLMD United States
- Employees
- IMNN N/A
- RLMD N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- RLMD Health Care
- Exchange
- IMNN Nasdaq
- RLMD Nasdaq
- Market Cap
- IMNN 13.6M
- RLMD 11.5M
- IPO Year
- IMNN 1985
- RLMD N/A
- Fundamental
- Price
- IMNN $0.92
- RLMD $0.30
- Analyst Decision
- IMNN Strong Buy
- RLMD Hold
- Analyst Count
- IMNN 2
- RLMD 4
- Target Price
- IMNN $20.50
- RLMD $4.25
- AVG Volume (30 Days)
- IMNN 148.4K
- RLMD 2.1M
- Earning Date
- IMNN 02-27-2025
- RLMD 03-18-2025
- Dividend Yield
- IMNN N/A
- RLMD N/A
- EPS Growth
- IMNN N/A
- RLMD N/A
- EPS
- IMNN N/A
- RLMD N/A
- Revenue
- IMNN N/A
- RLMD N/A
- Revenue This Year
- IMNN N/A
- RLMD N/A
- Revenue Next Year
- IMNN N/A
- RLMD N/A
- P/E Ratio
- IMNN N/A
- RLMD N/A
- Revenue Growth
- IMNN N/A
- RLMD N/A
- 52 Week Low
- IMNN $0.57
- RLMD $0.28
- 52 Week High
- IMNN $3.65
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- IMNN 53.96
- RLMD 30.81
- Support Level
- IMNN $0.81
- RLMD $0.28
- Resistance Level
- IMNN $0.93
- RLMD $0.36
- Average True Range (ATR)
- IMNN 0.05
- RLMD 0.04
- MACD
- IMNN -0.00
- RLMD 0.02
- Stochastic Oscillator
- IMNN 68.13
- RLMD 7.21
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.